

## Lockington, Elliott (SPAC/PSPC)

---

**From:** Sachdeva, Parvinder (IC)  
**Sent:** March 23, 2020 1:00 PM  
**To:** Parmar, Dovejot (SPAC/PSPC)  
**Subject:** FW: Time sensitive - COVID response technologies and supplies

Can you do a call with him to see what the process should be for him? Call me when you have a chance.

**From:** Ricky Mehra <mehra.rick@gmail.com>  
**Sent:** March 23, 2020 12:58 PM  
**To:** Sachdeva, Parvinder (IC) <parvinder.sachdeva@canada.ca>; navdeep.bains@parl.gc.ca  
**Subject:** Re: Time sensitive - COVID response technologies and supplies

Parvinder, there are many solution providers in CHI that we can gain access to solutions from. Below is one that has (depending on when you ask, moving quickly, we've lost a total of 300 over the last 24 hrs to other nation buyers) Phillips ventilators and we have a strong relationship with (we can work out favorable de-risked terms like net 30/45/60 invoicing; we can have a trusted party of the gov't inspect pre order if necessary as well).

### [Sinopharm](#)

China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.

Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.

The past years witnessed Sinopharm's steady and sound development. From 2009 to 2018, the CAGR of revenue and total assets reached 24.24% and 30.54% respectively. Sinopharm ranked 169th in Fortune Global 500 and the revenue of 2018 amounted to nearly 400 billion yuan..

Sinopharm has built a nationwide logistic and distributing network for drugs and medical devices and equipment, including 5 logistic hubs, more than 40 provincial-level centers and over 240 municipal-level logistic sites. By establishing the smart medical service system, Sinopharm delivers quality services to more than 230,000 corporate clients.

Sinopharm has an applied pharmaceutical research institute and an engineering design institute, both taking a leading position in China. Two Academicians of Chinese Academy of Engineering, 11 national R&D institutes, 44 provincial-level technology centers and over 5,000 scientists have made remarkable achievements. Sinopharm also chaired in setting over 530 national technical criteria, among which the EV71 vaccine, a first category new drug of China with Sinopharm holding complete independent intellectual

property right, reduces the morbidity of hand-foot-and mouth disease among Chinese children. The R&D and launch of sIPV ensures the progress of the national immunization program for polio.

Sinopharm has built up manufacturing and medicinal materials sites for biological drugs, narcotic and psychotropic drugs, anti-infectious drugs, oncology drugs, cardio-vascular drugs and respiratory drugs. Some of the production lines have been approved by the US FDA and EU authorities, and prequalified by WHO.

As world's 6th largest vaccine manufacturer, Sinopharm is able to produce all the vaccines in the National Vaccination Program and is the supplier of over 80% vaccines used in the Expanded Program on Immunization in China.

Sinopharm leads in TCM sector by establishing an integrated TCM industry chain that covers planting, R&D, pieces for decoction, formulated instant granules, and preparations. It is able to produce over 900 medicines, owns 15 China Time-honored Brands and 4 National Intangible Cultural Heritage medicines. Sinopharm has fostered 30 highly recognized events represented by CMEF (China International Medical Equipment Fair), serving the entire chain and many subdivisions concerning healthcare. These exhibitions and conferences have become a platform for exchange and cooperation that advances the whole industry. Sinopharm explored a new model of drugstores with extensive healthcare services. There are over 5,100 chain drugstores under the brands of Guoda, Jinxiang, Dadesheng and Tianyitang, providing convenient access for customers. Sinopharm forms a healthcare network consisting of regional healthcare groups in provinces of Henan, Hubei, Liaoning, and Heilongjiang. Sinopharm provides easier access to healthcare services for the people in dozens of our medical institutions with more than 10,000 beds in total.

Sinopharm broadens its international cooperation by founding 26 joint ventures with world-renowned pharmaceutical companies and trading with more than 120 countries and regions, including 60 Belt and Road countries.

The JE vaccine of which Sinopharm owns complete independent intellectual property right has been listed into the procurement catalog by the UN organizations to benefit the whole world. Sinopharm's production sites in Vietnam and Malaysia, along with the China-aided hospitals and mobile clinics constructed by Sinopharm in Myanmar and Cambodia, not only provide jobs for the local people, but also make great contributions to their well-beings.

As healthcare-centered financial services develop, an industry-and-finance model with Sinopharm features takes shape.

Guided by the core value of "all for health, health for all", Sinopharm shoulders the social responsibility of national medical and pharmaceutical reserve on a long-term basis with pride. In times of epidemics and disasters, it provides medicines, bio-products, traditional Chinese medicines, and medical devices promptly to the stricken areas not only at home, but also abroad as in Ecuador earthquake relief and in Myanmar influenza A/H1N1 prevention and control, contributing to ensure a sound public health condition for the people.

Sinopharm acts as the president enterprise in many influential associations such as China Pharmaceutical Industry Association, China National Narcotic Drugs Association, China Association of Pharmaceutical

Commerce, etc., and plays its role in preventing diseases, safeguarding people's health, and advancing the whole industry.

On Sun, Mar 22, 2020 at 9:48 PM Ricky Mehra <[mehra.rick@gmail.com](mailto:mehra.rick@gmail.com)> wrote:

Parvinder, thanks for taking time out of your day to help today. Below is the note I sent to Minister Bain's address earlier today - I'm sharing out of efficiency as I am limited on time.

Please advise what if anything additional you need? We can ensure someone on the ground (like a local consulate, other trusted 3rd party auditor) who can do a in person preview of solutions prior to execution of any deal. I believe escrow for payments should also not be a major issue.

I have access to the following:

- Ventilators (both Philips and AeonMed and a few others I'm still vetting)
- N95 / N99 / surgical masks
- Face Shields
- Goggles
- Isolation clothing
- Gloves
- Other PPEs
- Thermography / inspection and quarantine equipment
- COVID serology tests (used in Asia)

I am on a [panel](#) tomorrow morning on COVID response and then in meetings for work with W.H.O. and a potential new POC QPCR test tomorrow thru noon. That will give me a window 12-2p E tomorrow and then back on Zoom for a W.H.O. app meeting.

One of the people helping me with this is Tim Peters. He was awarded the Queens Diamond Jubilee Medal for community service and has strong contacts with Chief of Staff to Minister of Infrastructure, former Chief of Staff to PM Harper, Chief of Staff to Minister Bill Blair and more. There are well vetted people on the other end of this overseas.

Please let me know how best to proceed? These items are going to other parts of the world every minute.

----- Forwarded message -----

From: **Ricky Mehra** <[mehra.rick@gmail.com](mailto:mehra.rick@gmail.com)>

Date: Sun, Mar 22, 2020 at 5:19 PM

Subject: Time sensitive - COVID response technologies and supplies

To: <[navdeep.bains@parl.gc.ca](mailto:navdeep.bains@parl.gc.ca)>

Hi Navdeep, we met on a couple of occasions via Gianluca Cairo. This is [me](#). I have been attempting to fast track solutions for Ontario via some of the folks at Ontario Health but the expediency is not aligned with the global pace. See note below. **Can you please advise on the best channels for me to fast track vetted solutions into the front lines?**

There are some higher tech solutions that I think your group will appreciate that can be deployed rather rapidly than I am not focusing on with the group below. I would be interested in understanding what channels to drive those forward as well, secondarily.

-----

All, I am very aware of how stretched everyone is, but timing is critical as supplies are limited.

I simply need to understand if my hypothesis (as well as anecdotal insights from frontline staff) that Ontario hospitals are under resourced with supplies (ventilators, masks (n95, n99 and surgical and other PPE). The global demand is high and the finite supplies are being traded actively. There are some resources that are less finite and can be ordered in bulk on an on-going basis.

My background is here: [www.linkedin.com/in/rickymehravc](http://www.linkedin.com/in/rickymehravc)

I am also working around the clock with a global team that will be launching the official W.H.O. iOS and Android app. In those dealings, there is demand in our slack channel for the products I would like to share with Ontario, then rest of Canada.

Can someone please let me know if there is a need and if not, I can pivot my efforts to bringing these solutions to elsewhere on the planet where the demand is high. Also, can I be connected with counterparts across other provinces?

Kindly,

Ricky Mehra